Complement Activation Fragments Assay

Creative Biolabs provides complement activation fragments assay services for accurate evaluation of C3b/iC3b/C3d and C5b-9 deposition across antibodies, biologics, nanoparticles, cells, and biomaterials using customizable pathway-aware workflows.

Submit Your Request Now

Download our product brochure

Inquiry

Complement Activation Fragments Assay

Complement activation fragments provide some of the most informative readouts for understanding how a therapeutic candidate, biologic surface, delivery system, or pathological substrate interacts with the complement cascade. For drug developers, translational researchers, and platform teams working in immunology, inflammation, gene delivery, nanomedicine, and antibody engineering, these measurements deliver the mechanistic clarity needed to make confident decisions.

At Creative Biolabs, our complement activation fragments assay services are designed to quantify and interpret key deposited complement products across customized experimental settings. We help clients measure fragment deposition on cells, immune complexes, coated antigens, particles, biomaterials, and engineered delivery systems under physiologically relevant serum conditions.

Our service portfolio currently includes quantification of C3b deposition service and C5b-9 deposition measurement service. These services can be ordered independently or integrated into a broader complement characterization workflow together with C1q binding, CH50/AH50 testing, hemolysis inhibition, CDC evaluation, and complement inhibitor validation. By combining upstream, central, and terminal pathway readouts, we help generate a coherent and decision-ready complement profile for your candidate or model system.

Great Minds Choose Creative Biolabs

Partner with Us

Our Service Modules

Below is our custom aptamer development portfolio. Each module can be purchased independently or combined into a one-stop program.

Quantification of C3b Deposition Service

Our C3b deposition assay service is built for precise analysis of complement deposition at the central hub of the cascade. This assay helps determine whether a target surface is being tagged for immune recognition and whether the system is entering a state of local amplification.

C5b-9 Deposition Measurement Service

Our C5b-9 deposition measurement service is designed to assess terminal complement complex assembly on relevant biological or engineered surfaces. Because C5b-9 represents a late-stage product, its presence is often interpreted as evidence that activation has progressed beyond central amplification toward terminal effector function.

	C3b Deposition Quantification	C5b-9 Deposition Measurement
Ideal For	Antibody and Fc variant ranking Immune complex characterization CDC readiness assessment Complement inhibitor screening Biomaterial and nanoparticle opsonization profiling Cell surface complement coating studies Mechanistic studies in autoimmune and inflammatory models	Terminal complement pathway assessment Membrane attack complex research Cytotoxicity risk evaluation Therapeutic antibody terminal pathway characterization Biomaterial or nanocarrier terminal complement compatibility studies Complement blocker efficacy confirmation Comparative mechanistic studies across serum conditions or species
What We Can Evaluate	Antibody clones and isotypes Fc-engineered variants Glycoengineered antibodies Recombinant antigens or antigen-coated plates Tumor cells, primary cells, and immune cells Microbial surfaces Liposomes, LNPs, viral vectors, or polymeric particles Surface coatings, biomaterials, and functionalized interfaces	Cell surfaces under serum exposure Antibody-bound target cells Biomaterial interfaces Nanoparticles and vesicular systems Immune complexes Pathogen or surrogate particle models Customized coated substrates
What Clients Learn	Whether a test article promotes or inhibits C3 deposition Whether deposition is pathway selective Whether target coating is strong, weak, transient, or formulation dependent Whether a candidate is likely to trigger complement-driven opsonophagocytic consequences Whether upstream classical pathway engagement translates into meaningful central pathway activation	Whether complement progresses into terminal complex formation Whether deposition is robust enough to justify further CDC or membrane injury studies Whether inhibitors prevent terminal assembly Whether changes in formulation, surface chemistry, or target architecture alter terminal activation risk Whether lot or process modifications impact terminal complement behavior

Discuss Your Needs

Assay Formats

To match diverse target types and project objectives, we offer multiple assay formats.

Microplate-Based Deposition Assays

Cell-Based Deposition Assays

Flow Cytometry-Based Opsonization and Terminal Deposition

Customized Surface and Biomaterial Assays

Design Your Workflow

Typical Applications

Therapeutic Antibody Development

Ranking of IgG leads
Fc engineering assessment
Biosimilar comparability
Lot bridging
Candidate down-selection before CDC studies

Nanoparticles and Gene Delivery Systems

LNP formulation comparison
Surface chemistry optimization
PEGylation or ligand-density studies
Viral vector compatibility assessment
Exosome or EV immune interface profiling

Biomaterial and Device-Related Research

Coating optimization
Material surface screening
Comparative testing of modified versus unmodified substrates
Implant-relevant interface assessment
Blood-contacting surface evaluation

Autoimmunity and Inflammation Studies

Immune complex-driven activation studies
Altered self-surface analysis
Comparative patient or donor serum studies
Pathway dissection in disease models
Support for translational hypothesis testing

Add-On Assays That Sharpen Interpretation

Complement activation fragments provide powerful information on their own, but many programs benefit from adjacent assays that add functional or mechanistic depth.

Assays	Descriptions
C1q Binding Assay	Useful for understanding classical pathway initiation potential, especially in antibody programs.
C4d or Early Classical/Lectin Markers	Helpful for mapping activation further upstream when central or terminal deposition is observed.
Soluble Terminal Complement Quantification	Useful when clients want both deposited and soluble terminal pathway perspectives.
CH50 / AH50	Provides pathway activity context and can complement fragment deposition results in broader cascade studies.
CDC Assay	When terminal deposition is biologically meaningful, cell lysis studies can help determine whether complement engagement translates into functional cytotoxicity.
Hemolysis Inhibition Assay	A practical functional add-on when inhibitor programs or complement-regulating strategies are under evaluation.

Design Your Customization

Published Data

Case 1

Ex vivo test for measuring complement attack on endothelial cells

These tests consist of the quantification of complement activation products (C3 activation fragments and C5b-9) deposits on EC by immunofluorescence (IF) measured by confocal microscopy or flow cytometry (fluorescence-activated cell sorting, FACS) after incubation with a serum sample of interest.

Measuring complement attack on endothelial cells. (OA Literature) Fig. 1 Comparative analysis of different protocols used for the ex vivo complement activation test with endothelial cells.^1,2

References

Meuleman, Marie-Sophie, et al. "Ex vivo test for measuring complement attack on endothelial cells: from research to bedside."Frontiers in immunology 13 (2022): 860689. https://doi.org/10.3389/fimmu.2022.860689
Distributed under Open Access license CC BY 4.0, without modification.

What Our Clients Say

"We were comparing several antibody candidates with different Fc designs and needed to understand which variants truly engaged complement in a meaningful way. The C3b deposition results from Creative Biolabs clearly differentiated the panel and gave us confidence in selecting the most promising leads for downstream CDC studies."

— Senior Scientist, Antibody Discovery

"Our project focused on a complement inhibitor, and we needed more than a general pathway readout. The team designed a study that allowed us to evaluate both C3 fragment deposition and C5b-9 formation under matched conditions. This gave us a much clearer view of where our molecule was acting in the cascade. The study outcome strengthened our mechanism package significantly."

—Director of Translational Pharmacology, Complement Therapeutics Company

"We approached Creative Biolabs with a nonstandard nanoparticle system and were concerned that a generic assay format would not be informative. Their scientists worked with us to define the right matrix conditions, controls, and detection strategy."

— Principal Scientist, Nanomedicine Research

"What stood out to us was the team's ability to explain the biological meaning behind the results. They did not simply deliver numbers; they connected the data to complement pathway behavior and helped us understand which follow-up studies would be most valuable. That made the collaboration much more efficient."

— Associate Director, Immunology R&D

Frequently Asked Questions

Should I choose C3b deposition analysis, C5b-9 analysis, or both?

The answer depends on your scientific objective. If you want to understand early-to-central complement engagement, compare opsonization levels, or assess pathway amplification, C3b deposition is often the right starting point. If you are more concerned with terminal pathway activity, membrane attack complex formation, or downstream injury potential, C5b-9 may be more informative. In many projects, combining both gives the most complete picture.

Can you evaluate complement inhibitors using this service?

Yes. These assays are well suited for complement inhibitor development because they can directly show whether a test article reduces deposition of central or terminal complement products. Depending on assay design, they may help determine whether an inhibitor acts upstream, centrally, or closer to the terminal pathway.

What sample types can be tested?

We can support a range of sample and target types depending on project design. These may include purified antibodies, recombinant proteins, immune complexes, cultured cells, primary cells, nanoparticles, extracellular vesicles, viral vectors, beads, coated antigens, and selected biomaterial surfaces. If your material is unconventional, our team can evaluate whether a customized workflow is appropriate.

Do you offer pathway-specific assay design?

Yes. When scientifically appropriate, we can design studies to investigate the relative involvement of the classical, lectin, or alternative pathway. This may include specific serum conditions, depletion or reconstitution strategies, and carefully selected controls that help distinguish pathway contributions.

Which species are supported?

Human serum is commonly used and often preferred for translational relevance, but other species may be supported depending on the project. Available options can include mouse, rat, and non-human primate matrices, subject to experimental suitability and study goals.

How much sample is required?

Sample requirements vary based on assay format, number of conditions, replicate strategy, and whether optimization is needed. During project planning, we provide sample guidance tailored to your study design. If sample amount is limited, we can often suggest a phased or prioritized approach.